KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $585.7 million.

  • Eli Lilly's Depreciation & Amortization (CF) rose 2071.31% to $585.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 1301.64%. This contributed to the annual value of $2.0 billion for FY2025, which is 1301.64% up from last year.
  • Latest data reveals that Eli Lilly reported Depreciation & Amortization (CF) of $585.7 million as of Q4 2025, which was up 2071.31% from $470.0 million recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Depreciation & Amortization (CF) registered a high of $585.7 million during Q4 2025, and its lowest value of $348.9 million during Q2 2022.
  • Over the past 5 years, Eli Lilly's median Depreciation & Amortization (CF) value was $405.8 million (recorded in 2023), while the average stood at $418.1 million.
  • In the last 5 years, Eli Lilly's Depreciation & Amortization (CF) skyrocketed by 2803.36% in 2021 and then crashed by 1684.65% in 2023.
  • Eli Lilly's Depreciation & Amortization (CF) (Quarter) stood at $445.7 million in 2021, then fell by 15.86% to $375.0 million in 2022, then rose by 3.31% to $387.4 million in 2023, then grew by 25.25% to $485.2 million in 2024, then grew by 20.71% to $585.7 million in 2025.
  • Its Depreciation & Amortization (CF) was $585.7 million in Q4 2025, compared to $470.0 million in Q3 2025 and $478.5 million in Q2 2025.